N/A
N=32
Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
Cardiovascular Diseases · Endotoxemia · Endothelial Dysfunction · Postprandial Hyperglycemia · Gut Health
Bottom Line
View on ClinicalTrials.gov: NCT03624569 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Endotoxin — 21.2; 23.3 EU/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bagel (Other); Potato (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ohio State University
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endotoxin |
21.2; 23.3 | — |
| PRIMARY Vascular Endothelial Function |
-259; -198 | — |
| SECONDARY Fasting Glucose Day 0 |
104; 109.5 | — |
| SECONDARY Fasting Glucose Day 14 |
101.9; 102.3 | — |
| SECONDARY Fasting Insulin Day 0 |
21.1; 17.0 | — |
| SECONDARY Fasting Insulin Day 14 |
14.2; 14.9 | — |
| SECONDARY Postprandial Insulin |
5940; 7086 | — |
| SECONDARY Postprandial Glucose |
2649; 2808 | — |
| SECONDARY Fasting Endotoxin |
26.6; 22.3 | — |
| SECONDARY Postprandial Endotoxin |
450; -120 | — |
| SECONDARY Lactulose/Mannitol Ratio |
.154; .151 | — |
| SECONDARY Sucralose/Erythritol Ratio |
.0148; 0.01667 | — |
| SECONDARY Fecal Butyrate |
21.3; 17.9 | — |
| SECONDARY Fecal Acetate |
52.3; 46.6 | — |
| SECONDARY Fecal Propionate |
23.1; 19.3 | — |
| SECONDARY Postprandial Cholecystokinin |
-196; -67 | — |
| SECONDARY Fasting Cholecystokinin |
14.3; 14.2 | — |
| SECONDARY Postprandial NOx |
-240; -433 | — |
| SECONDARY Fasting NOx |
29.8; 30.1 | — |
| SECONDARY Postprandial Malondialdehyde (MDA) |
57.2; 45.4 | — |
| SECONDARY Fasting Malondialdehyde (MDA) |
1.78; 1.93 | — |
| SECONDARY Fasting Vascular Endothelial Function |
7.2; 8.7 | — |
| SECONDARY Vitamin C |
47.5; 52.5 | — |
| SECONDARY cIMT |
0.603; 0.609 | — |
| SECONDARY Day 14 BMI |
35.1; 35.2 | — |
| SECONDARY Day 0 Waist Circumference |
108.5; 119.1 | — |
| SECONDARY Day 14 Waist Circumference |
107.8; 107.5 | — |
| SECONDARY Day 0 Diastolic Blood Pressure |
81.5; 81.9 | — |
| SECONDARY Day 14 Diastolic Blood Pressure |
75.9; 77.7 | — |
| SECONDARY Day 0 Systolic Blood Pressure |
123.1; 119.1 | — |
| SECONDARY Day 14 Systolic Blood Pressure |
113.6; 114.6 | — |
| SECONDARY Day 0 BMI |
35.6; 35.7 | — |
Summary
This study is focused on assessing potential health benefits of daily consumption of potatoes, specifically its resistant starch content (i.e. nondigestible carbohydrate), on blood vessel and gut health function in adults with metabolic syndrome. It is expected that the daily consumption of potatoes for two weeks, within a diet that follows the Dietary Guidelines for Americans, will improve blood vessel function in association with decreasing gut permeability ("leaky gut") that results in the absorption of bacterial toxins that reside in the intestine. Outcomes will therefore support dietary recommendations for potatoes to support vascular and gastrointestinal health.
Eligibility Criteria
Inclusion Criteria
- Fasting glucose 100-125 mg/dL
- Waist circumference >102 cm (men), >88 cm (women)
- Fasting triglyceride >150 mg/dL
- Fasting HDL cholesterol 1-mo)
- Free of gastrointestinal disorders, cardiovascular disease, cancer
- No recent use of antibiotics or any medications affecting glycemia, lipidemia, or blood pressure
Exclusion Criteria
- Use of anti-inflammatory agents or probiotics
- Vegetarian, gluten-intolerant, carbohydrate-restricted diet
- Alcohol intake >2 drinks/d
- >7 hours/week of aerobic activity
- Women who are pregnant or lactating or have initiated or changed birth control in the past 3-months
- Taking medications that affect blood sugar, blood pressure, blood vessel health, or inflammation
- High blood pressure or any vascular diseases
- HIV, hepatitis, or blood disorders such as hemophilia
- Gastrointestinal disorders
- Cancer (current or past history)
- Anemia
Data sourced from ClinicalTrials.gov (NCT03624569). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.